Apnimed Announces a Robust Slate of Presentations at SLEEP 2024, Including an Analysis of the Prevalence of Obesity in ...
New Data Underscore the Need for New OSA Treatments That Go Beyond Weight Loss to Address the Neuromuscular Root Cause of the Disease Oral Presentations include Rationale and Design of SynAIRgy Phase 3 Study for AD109, a Potential Nighttime Oral Drug …